Genesis Biopharma, a biotechnology company developing targeted cancer therapies, has named Laszlo Radvanyi, Ph.D., to its Scientific and Medical Advisory Board.

"Dr. Radvanyi's research using tumor-infiltrating lymphocytes (TILs) for the treatment of Stage IV metastatic melanoma, including ongoing phase I and phase II clinical trials, complements the development of our product candidate Contego for the treatment of Stage IV metastatic melanoma," stated Anthony J. Cataldo, chairman and CEO of Genesis Biopharma. 

Dr. Radvanyi worked in the immunology group at Sanofi-Pasteur in Toronto as a senior scientist, and later joined the faculty of the University of Texas, MD Anderson Cancer Center as an Associate Professor.